A dual-targeting lipid nanoparticle delivery system for precision phage therapy against multidrug-resistant Gram-negative bacteria
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
In murine models of Pseudomonas aeruginosa infection, AbLCP achieved superior bacterial clearance and up to 10 3 -fold reduction in bacterial burden at a 10 3 -fold lower effective dose than free polymyxin B, with 67-fold selective accumulation at infection sites, and attenuated systemic inflammation and preservation of gut microbiota.
Appeared: Sunday, November 1. Science Advances. Peer-reviewed journal.